Contrary to current models, Scherrer et al. (2009) provide evidence that mu and delta opioid receptors are not expressed by the same pain-sensing neurons. In mice, agonists for these receptors produce analgesia restricted to either noxious heat or mechanical stimuli, implying that the receptors act on distinct fibers to mediate completely different types of pain relief.
It is relatively rare in neurobiology that a discovery forces a sudden re-evaluation of an established dogma. The paper by Scherrer et al. (2009) in this issue challenges the prevailing view concerning opioid receptors and the analgesia they produce. The current models are predicated on interactions in primary sensory neurons between two different types of opioid receptors (mu and delta) and with the neuropeptide substance P. Scherrer et al. provide evidence that these interactions are unlikely to occur for a very simple reason-the key players do not appear to be coexpressed in the same neuron.
Morphine was isolated from opium in 1805 by Sertürner, who named the compound after the Greek god of dreams because of the state of altered consciousness it produced. While "in the arms of Morpheus" there is also profound analgesia, making morphine the gold standard for pain relief. The 1973 discovery of opioid-binding proteins by Pert and Snyder provoked a race to identify the receptors, which were differentiated pharmacologically into distinct subtypes by Martin. The delta opioid receptor (DOR) was the first to be cloned independently by Kieffer and Evans in 1992, soon followed by the mu opioid receptor (MOR). These are both inhibitory G protein-coupled receptors (GPCRs), as is the kappa opioid receptor (KOR). Once it was shown that knocking out the MOR gene completely eliminates the analgesic action of morphine, the pivotal role of this receptor in pain biology was firmly cemented (Matthes et al., 1996) . The role of DOR remained more complex; nevertheless, there is reduction in some analgesic signals in mice lacking DOR and, perhaps more surprisingly, decreased analgesic tolerance to morphine, hinting at possible interaction between the MOR and DOR (Zhu et al., 1999) .
Because activation of MOR produces not only analgesia but also respiratory depression, sedation, nausea, and constipation, as well as euphoria, there has been an active search for opiates with the analgesic efficacy of MOR agonists but without their side effects, dependence, tolerance, and abuse liability-so far with no clinical success. KOR agonists produce intense dysphoria and diuresis, and some DOR agonists induce seizures, both showstoppers. However, the insights generated by Scherrer et al. make it time to reopen the DOR as an analgesic target.
MOR is expressed by a subset of nociceptor (noxious stimulus detecting) sensory neurons that express the neuropeptide substance P and the noxious heat transducer TRPV1. MOR on presynaptic axon terminals in the spinal cord reduces transmitter release by inhibiting voltage-gated calcium channels, diminishing sensory input from nociceptors to the central nervous system (CNS). The receptor is also located postsynatically, where it activates GIRK potassium channels to reduce excitability. MOR is widely expressed in the CNS. However, it is likely that the spinal cord is a major contributor to analgesia because intrathecal administration of MOR agonists produces analgesia, and that of MOR antagonists reduces analgesia produced by systemic opiates.
DOR too is expressed in primary sensory neurons (and in many CNS neurons) and, until the study of Scherrer et al., was thought to be coexpressed in exactly the same peptidergic nociceptor neurons as MOR. This combined with data from heterologous expression systems showing that the receptors form heterodimers and the finding that DOR antagonism leads to a reduction in morphine tolerance led to the suggestion that MOR-DOR complexes are an important contributor to the development of tolerance to MOR agonists (Decaillot et al., 2008; Gomes et al., 2004) . Although the study of Scherrer et al. does not exclude such MOR-DOR interactions in CNS neurons, it suggests minimal opportunity for heterodimer formation in nociceptors.
DOR is also proposed to interact via an extracellular loop with substance P to mediate its trafficking to the membrane of nocicepter central terminals in the spinal cord (Guan et al., 2005) . This model is important because immunohistochemical studies report that DOR is absent from the presynaptic membrane under control conditions, which implies no activity in response to DOR agonists in the resting state. Instead, DOR is supposed to be stored in the membrane of large dense core vesicles (LDCVs) that contain substance P and becomes incorporated into the plasma membrane only on exocytosis of the vesicles (Bao et al., 2003; Gendron et al., 2006; Guan et al., 2005) . Hence, activation of nociceptors would promote a cumulative increase in responsiveness to DOR agonists, implying efficacy only in those pathological circumstances with ongoing sensory input and release of substance P (Gendron et al., 2006; Guan et al., 2005) . Alas this model looks as if it may have to be abandoned because Scherrer et al. show that DOR is not expressed in substance P-containing neurons. In addition, it looks like it behaves as a prototypic GPCR with membrane expression in basal conditions and internalization on activation, rather than the use-dependent insertion into the membrane suggested in current models.
What has so muddied the waters? It turns out that perhaps all commercially available antibodies raised against DOR peptides recognize a protein that is still present in mice lacking DOR and all immunohistochemistry using these antibodies is therefore suspect. Scherrer et al. use a DOR-enhanced green fluorescent protein (EGFP) reporter mouse to show that the receptor is localized in the set of presumptive nociceptor neurons that do not express substance P. The often made jest that the most valuable contribution of knockouts is to test antibody specificity is not a joke. What protein these antibodies recognize and its involvement in opioid receptor biology are now open questions, as is how substance P may contribute to morphine tolerance. DOR reporters with Myc and hemagluttinin tags are expressed in LDCVs whereas those with a smaller GFP tag are located on the cell surface and interact with agonists (Wang et al., 2008) , a further source of potential artifact.
Scherrer et al. argue that expression of MOR in TRPV1-expressing nociceptor neurons contributes to analgesia for heat pain whereas DOR action in nonpeptidergic sensory neurons results in reduction only in mechanical pain. These results are intriguing, suggesting that although most nociceptors are activated by both heat and mechanical stimuli, the input somehow and unexpectedly enters the CNS via anatomically distinct channels. This appears difficult to reconcile though with the very substantial clinical experience that morphine's analgesic actions are not limited to heat pain and the observation that DOR agonists can very effectively reduce heat pain after peripheral inflammation (Codd et al., 2009 ). Many exciting questions remain, not least whether DOR agonists will join MOR agonists in the pantheon of clinically useful opiate analgesics if their propensity to induce seizures can be fully overcome.
The vascular system comprises an elaborate network of arteries, capillaries, and veins that penetrate all body tissues to provide oxygen and nutrients and to remove waste. During development, new blood vessels form by sprouting into avascular zones in a process known as angiogenesis. The primary driver of angiogenesis is hypoxia (lack of oxygen). Hypoxia accompanies tissue growth and triggers the release of angiogenic growth factors, the best studied of which is vascular endothelial growth factor (VEGF). Endothelial cells line blood vessels and normally rest in a quiescent state. In response to VEGF, they become activated and promote the sprouting of new vessels. The tips of these sprouts are formed by specialized endothelial cells called tip cells (Figure 1 ). Tip cells are migratory and extend numerous filopodia to sense their
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